Solid Carcinoma Clinical Trial
Official title:
Observational Immunomonitoring Study of NK/T and Myelocites Status in Cancer Patients and Controls
Tumors have a systemic immune modifying effect. They affect the immune system similarly to
states of chronic inflammation and these effects can:
- be monitored through analysis of nk t and myeloid cells mainly through studies of the
zeta chain but also through other means
- may be decreased following effective anticancer therapy - may even be used to study the
effectiveness of anticancer therapy
- are important to monitor if the investigators plan on formulation of systemic immune
therapy Thus immumonitoring of systemic blood cells may turn out to be an important
prognostic and predictive factor in many cancer types
CD247 Known also as the zeta chain is important for relaying T-cell induced signal
transduction.
Interestingly studies by Baniash and others have demonstrated that this chain is down
regulated in states of chronic inflammation and cancer in peripheral blood T cells and also
in NK cells However there has not been a prospective study of this marker in cancer and
control patients such a study will reveal not only the levels of CD247 in immune cells of
cancer patients compared to controls but may reveal the effect of anticancer therapies on
CD247 in cancer patients such a study may contribute significantly to our ability to monitor
systemic immune system characteristics in cancer patients and help in any further studies of
immunomodulation such as vaccination schemes in such patients
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04552288 -
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
|
Phase 2 | |
| Completed |
NCT05054374 -
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06051214 -
Thrombin Generation and Prediction of Thromboembolic Events in Oncology Patients at Risk
|
N/A | |
| Not yet recruiting |
NCT05533983 -
FMT With Nivolumab in Patients With Advanced Solid Cancers Who Have Progressed During Anti-PD-(L)1 Therapy
|
N/A | |
| Completed |
NCT03590808 -
Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor
|
N/A | |
| Recruiting |
NCT06104488 -
A Study of Avutometinib for People With Solid Tumor Cancers
|
Phase 1 | |
| Recruiting |
NCT03129139 -
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05500508 -
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05678010 -
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
|
Phase 1 | |
| Recruiting |
NCT05346484 -
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT03775525 -
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04264975 -
Utilization of Microbiome as Biomarkers and Therapeutics in Immuno-Oncology
|
N/A | |
| Completed |
NCT04644874 -
Geriatric Oncology Screening of Older Patients With Solid Cancers
|
||
| Recruiting |
NCT04443088 -
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT04545827 -
Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours
|
Phase 1 | |
| Completed |
NCT04747249 -
Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19
|
N/A | |
| Completed |
NCT03536728 -
Oral AMXT 1501 Dicaprate in Combination With DFMO
|
Phase 1 | |
| Active, not recruiting |
NCT02974738 -
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
|
Phase 1 | |
| Recruiting |
NCT05868226 -
PRE-I-SPY Phase I/Ib Oncology Platform Program
|
Phase 1 | |
| Completed |
NCT04200963 -
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
|
Phase 1 |